NASDAQ: AXDXAccelerate Diagnostics Inc Stock
$0.86+0.09 (+11.69%)
Updated Apr 19, 2024
AXDX Price
$0.86
Fair Value Price
N/A
Market Cap
$18.61M
52 Week Low
$0.73
52 Week High
$11.90
P/E
-0.17x
P/B
-0.94x
P/S
4.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.06M
Earnings
-$61.62M
Gross Margin
21.1%
Operating Margin
-439.71%
Profit Margin
-511%
Debt to Equity
-2.58
Operating Cash Flow
-$40M
Beta
1.17
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AXDX Overview
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AXDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AXDX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AXDX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AXDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AXDX due diligence checks available for Premium users.
Be the first to know about important AXDX news, forecast changes, insider trades & much more!
AXDX News
Valuation
AXDX fair value
Fair Value of AXDX stock based on Discounted Cash Flow (DCF)
Price
$0.86
Fair Value
$35.10
Undervalued by
97.55%
AXDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AXDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
28.69x
Market
40.51x
AXDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.94x
Industry
3.63x
AXDX's financial health
Profit margin
Revenue
$3.0M
Net Income
-$13.0M
Profit Margin
-429.4%
AXDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AXDX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$31.4M
Liabilities
$51.3M
Debt to equity
-2.58
AXDX's short-term assets ($24.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AXDX's long-term liabilities ($39.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AXDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AXDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.8M
Investing
-$110.0k
Financing
$107.0k
AXDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AXDX vs Medical Device Stocks
Accelerate Diagnostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.